Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.

• Quantum BioPharma executive co-chairman and co-founder Anthony Durkacz appeared as a guest on the BioMedWire Podcast.
• Durkacz outlined the company’s strategy for advancing Lucid-MS, the company’s lead drug candidate for multiple sclerosis.
• The Quantum BioPharma exec also provided an update on unbuzzd, the company’s innovative, clinically validated alcohol metabolism accelerator designed to help sober people up faster.

Executive thought leadership has become an increasingly important component of corporate communications, particularly in highly specialized industries such as biotechnology. Through podcasts, interviews and other educational forums, company leaders can explain complex technologies, discuss development strategies and provide context that is often difficult to capture in traditional press releases. That approach was recently on display when Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) executive co-chair and co-founder Anthony Durkacz appeared as a guest on the BioMedWire Podcast.

Quantum BioPharma is a biopharmaceutical company focused on developing treatments for neurodegenerative, metabolic and alcohol-misuse disorders, with Lucid-MS and its ownership in commercially product unbuzzd(TM). During the interview, Durkacz outlined the company’s strategy for…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

This contant was orignally distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast.